Reduction in CD8+ cell noncytotoxic anti-HIV activity in individuals receiving highly active antiretroviral therapy during primary infection

Citation
Sa. Stranford et al., Reduction in CD8+ cell noncytotoxic anti-HIV activity in individuals receiving highly active antiretroviral therapy during primary infection, P NAS US, 98(2), 2001, pp. 597-602
Citations number
42
Categorie Soggetti
Multidisciplinary
Journal title
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
ISSN journal
00278424 → ACNP
Volume
98
Issue
2
Year of publication
2001
Pages
597 - 602
Database
ISI
SICI code
0027-8424(20010116)98:2<597:RICCNA>2.0.ZU;2-F
Abstract
Recent advances in the ability to detect people at the early stages of HIV infection now permit the initiation of antiretroviral treatment before the full complement of antiviral immune responses has evolved. However, the inf luence of early treatment interventions on the developing anti-HIV immune r esponse is unknown. This study investigates the impact of standard highly a ctive antiretroviral therapy (HAART) during the primary stages of HIV infec tion on the plasma HIV-1 RNA level, CD4(+) and CD8(+) lymphocyte counts, an d the CD8(+) cell anti-HIV response. Individuals treated with HAART within 6 months of infection showed dramatic and rapid reductions in HIV-1 RNA lev els along with modest increases in CD4(+) cell number and decreases in CD8( +) cell numbers, A significant reduction in the level of CD8(+) cell noncyt otoxic suppression of HIV replication was observed over time in most partic ipants receiving HAART, Importantly, those individuals choosing not to rece ive therapy maintained low but detectable HIV-1 RNA levels and showed no re duction in their CD8(+) cell antiviral response. These results suggest that either continued antigenic challenge is required to sustain CD8(+) cell-me diated anti-HIV activity, or that HAART has some inhibitory effect on this important immunologic function during the early stages of infection.